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CONTINUING EDUCATION
A Review of Common Drug-drug and Food-drug Interactions 
Associated with Cardiovascular Medications
By Raymond Kho, Pharm.D. Candidate, Sarah Kim, Pharm.D. Candidate, Stacy Lee, Pharm.D. Candidate, and Laura Tsu, 
Pharm.D., BCPS, Midwestern University College of Pharmacy - Glendale
Goal:
This home-study CPE activity has been developed to educate 
pharmacists on the common drug-drug and food-drug 
interactions associated with cardiovascular medications.
Objectives
1. Identify the uses of various over-the-counter (OTC) products 
of interest in cardiovascular patients
2. Describe the mechanism of action (MOA) of various food-
drug/drug-drug interactions involving cardiovascular medica-
tions (statins, antiplatelet therapies, warfarin, red yeast rice)
3. Explain the clinical significance of these interactions in medi-
cation therapy
4. Relate recommendations with current clinical evidence
5. Formulate an appropriate treatment plan given a possible 
drug interaction scenario for cardiovascular patients
Clopidogrel and PPIs
Clopidogrel (Plavix®) is an antiplatelet medication used to 
lower the risk of ischemic events in patients who suffer from 
coronary artery disease (CAD), peripheral artery disease (PAD), 
or who have undergone percutaneous coronary intervention 
(PCI) or coronary artery bypass grafting (CABG). As a hepatical-
ly activated prodrug, it must first be metabolized via CYP2C19 
before it can take effect.1 Once activated, clopidogrel prevents 
the activation of platelets by inhibiting adenosine diphosphate 
(ADP) receptors, specifically P2Y12 receptors, on the platelet 
surface.2 ADP is an endogenous prothrombic molecule that 
is crucial for the initiation of clot formation. As shown in the 
Clopidogrel in High-Risk Patients with Acute Nondisabling 
Cerebrovascular Events (CHANCE) trial, clopidogrel with aspirin 
in dual-antiplatelet therapy has shown added benefits in the 
prevention of ischemic events in patients who suffered recent 
transient ischemic attack (TIA) or minor stroke, compared to 
these medications alone.3 The Clopidogrel for the Reduction of 
Events During Observation (CREDO) trial found an increase in 
thromboembolic protection with dual-antiplatelet therapy in 
patients who had recently undergone PCI.4 Studies have also 
shown a trend toward fewer ischemic strokes and heart failure 
in those with non-ST elevation acute coronary syndrome taking 
dual-antiplatelet therapy, as well as a decreased occurrence of 
stent thrombosis compared to warfarin-aspirin therapy.5,6
Interaction
Due to the inherent bleeding concerns that accompany the use 
of antiplatelet drugs and aspirin, there is legitimate controversy 
over the concomitant use of these agents. Studies have shown 
that there may be an increased risk of gastrointestinal (GI) 
bleeding associated with clopidogrel-aspirin dual therapy and 
that proton-pump inhibitors (PPI) may be beneficial 
in reducing these events.7 PPIs are known inhibitors 
of CYP2C19 with differing degrees of inhibition at-
tributed to each PPI; therefore, new concerns arise 
regarding PPIs decreasing the conversion of clopido-
grel to its active form and the subsequent increased 
risk of thromboembolic events. Recent studies have 
been performed to more clearly 
elucidate the risk versus benefit of concomitant use 
of PPIs in patients undergoing clopidogrel-aspirin 
therapy, which have important implications for 
pharmacists who may encounter this regimen in 
practice. 
      There are studies that suggest PPIs like 
omeprazole may have an effect on the activation of 
clopidogrel8 and lead to increased platelet reactivity 
in patients who are at risk for clots. These findings 
are supported by studies that have shown that 
patients using PPIs with clopidogrel suffer worse 
outcomes9,10 versus those not using PPIs or PPIs 
that are only slightly metabolized by CYP2C19, like 
pantoprazole. From these studies, it was believed 
that alternatives for CYP2C19-metabolized PPIs, 
such as histamine-2-receptor antagonists or differ-
ently metabolized PPIs would provide more benefit 
to patients on clopidogrel-aspirin therapy. 
      However, conflicting research suggests that the 
pharmacodynamic interactions observed between 
PPIs and clopidogrel are not universal among PPIs 
and are mostly limited to omeprazole.11,12 This is 
supported by the Clopidogrel and the Optimization 
of Gastrointestinal Events Trial (COGENT), a ran-
domized controlled trial that sought to investigate 
the efficacy and safety of clopidogrel with PPIs in 
patients receiving aspirin. Bhatt et al. found that 
PPI use significantly reduced bleeding risks in these 
patients and concluded that the use of omeprazole 
and clopidogrel did not result in clinically significant 
cardiovascular interactions7. Recent retrospective 
observational reviews also paint a contradictory 
picture. In their analysis, Dunn et al. found that 
PPI-use in the CAPRIE study correlated with reduced 
effects of clopidogrel, at least in patients who were 
not also receiving aspirin, while data from the 
CREDO trial showed no increase in cardiovascular 
events in the PPI group.13 Currently, there is no 
consensus regarding the effect PPI-use has on 
outcomes in patients on dual-antiplatelet therapy 
and further studies are needed to more clearly 
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understand their relationship.
Recommendation
In 2010, the American College of Cardiology Foundation 
(ACCF), American College of Gastroenterology (ACG), and 
American Heart Association (AHA) issued a consensus 
document to address the controversy regarding PPIs and 
drugs like clopidogrel. The document acknowledged the 
pharmacokinetic plausibility of a drug-drug interaction 
involving CYP2C19 and the need for further research into 
its clinical significance. For healthcare professionals, these 
organizations suggest careful discretion for patients on GI 
prophylaxis and antiplatelet therapies. Although PPIs are 
considered appropriate in patients undergoing antiplatelet 
therapy, the risks and benefits associated with 
cardiovascular (CV) and GI complications must be 
considered as well.14 Risk factors for GI bleed such as history 
of GI bleed, advanced age, and use of corticosteroids must 
be assessed, and PPI use should be reserved for those who 
are at highest risk. A patient’s physician should be consulted 
if concerns of negative CV outcomes outweigh the risk of 
developing a GI bleed.
Niacin
Nicotinic acid (niacin) is recommended as a therapeutic 
option for the treatment of dyslipidemia due to its effective-
ness in favorably affecting all lipid parameters: it increases 
high density lipoprotein (HDL) cholesterol by 15-35%, 
decreases low density lipoprotein (LDL) cholesterol by 
5-25%, and additionally decreases triglycerides (TGs) by 
20-50% with doses of 2-3 g/day.15 It is thought that niacin 
achieves this by working on multiple tissues, proteins, and 
enzymes.16 In the liver, niacin has three functions: decrease 
TG synthesis to ultimately decrease very low density lipo-
proteins (VLDL) and LDL secretion, inhibit removal of HDL 
from circulation, and increase HDL biogenesis. Lipid-inde-
pendent effects include decreased monocyte adhesion and 
infiltration, increased HDL function, and decreased foam cell 
formation.These effects, however, have not been conclu-
sively shown to translate into improved clinical outcomes 
in clinical trials.17, 18 In particular, the recent HPS2-THRIVE 
randomized-controlled trial confirmed the results of the 
AIM-HIGH trial, demonstrating no additional benefit of 
adding extended release (ER) niacin and laropiprant (to 
decrease flushing) to first-line therapy.19 Newly released 
hyperlipidemia guidelines include this information and 
recognize that lowering non-HDL-C when LDL-C is at target 
levels yields no additional benefit in reducing arterioscle-
rotic cardiovascular disease (ASCVD) events.20 These new 
guidelines focus on statin therapy, finding no data support-
ing the efficacy of adjunct non-statin agents in reducing 
ASCVD events. Adjunct therapy with agents shown to re-
duce ASCVD risk in RCTs is only recommended for high-risk 
individuals who have insufficient response to statins, who 
cannot tolerate recommended higher statin doses, or can-
not tolerate statins at all. Given the results of the HPS2-
THRIVE and AIM-HIGH trials, niacin may not qualify as a 
non-statin alternative under these new guidelines. 
Interaction
Some of niacin’s side effects stem from how its different 
formulations are metabolized by the liver with first-pass 
metabolism.21 Niacin is metabolized by two pathways 
that result in either conjugation or amidation. The 
conjugative pathway, a low-affinity and high-capacity 
pathway, is only utilized when the amidation pathway 
(high-affinity and low-capacity) is saturated. It is these 
glycine conjugated products, such as nicotinuric acid, 
that lead to prostaglandin-mediated vasodilation and 
flushing. Tolerance to flushing may develop but not 
before many discontinue therapy due to the discomfort. 
The high-affinity and low-capacity amidation pathway 
generates nicotinamide and pyrimidine metabolites 
that are associated with hepatotoxicity.  Hepatotoxicity 
caused by niacin has been described to have an onset 
of 1 week to 48 months.22 This usually presents with 
elevated aminotransferase levels, but there are mixed 
reports of patterns of hepatocellular and cholestatic 
injury. Other effects include nausea and vomiting and a 
sharp decrease in serum lipid levels, which is reversible, 
with a recovery period of 1-2 months following discon-
tinuation. Although fulminant hepatic failure is rare, 
hepatotoxicity is a concern with doses exceeding 2-3 g/
day.
       Niacin is available in many formulations: 
immediate-release (IR), extended-release (ER) and 
sustained-release (SR). Most formulations are available 
as OTC supplements that have not been reviewed by 
the FDA for safety and efficacy as agents for dyslipid-
emia, with only a few that have FDA approval.23 Since 
IR products will quickly saturate the amidation pathway, 
most of the IR dose will be metabolized by the conju-
gative pathway such that the primary side effect will be 
flushing. In contrast, SR products slowly release niacin 
over time which is continuously metabolized by the 
amidation pathway, resulting in increased risk of hep-
atotoxicity. Thus, IR use is limited by extreme flushing 
while SR use is limited by risk of hepatoxicity. Patients 
who take IR niacin products at therapeutic doses almost 
never experience hepatotoxicity, but half of those who 
take SR niacin will have elevated transaminases. Nias-
pan®, the only available ER product, seems to be equally 
metabolized by the two pathways such that it has 
relatively moderate levels of flushing and hepatotoxicity. 
In a clinical trial, only 5% of patients stopped therapy 
due to flushing and it has not been shown to cause an 
increase in aminotransferase levels at doses of 2 g/day 
or lower. This middle-of-the-road product is preferable, 
but currently, it is only available prescription-only.  
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Recommendation
Due to the wide availability and range of niacin products 
on the market, any patient taking these products should 
be advised about the side effects specific to the formula-
tion that they are taking. Patients might readily purchase 
OTC niacin products without knowledge of the risks of 
flushing and hepatoxicity. Given the moderate side effect 
profile of Niaspan®, it would be the preferred niacin 
product; however, there may be an associated increase 
in cost. In addition to flushing and hepatotoxicity, niacin 
is known to cause hyperglycemia so caution must also be 
taken with diabetic patients. Pharmacists and physicians 
should monitor for these side effects and start with lower 
doses. With the recent results from clinical trials and 
hyperlipidemia guidelines, it is even debatable whether 
adding niacin is beneficial for decreasing clinical outcomes 
in patients with dyslipidemia. 
Fish Oil and Warfarin
Therapy with fish oil supplements is indicated for those 
with CAD and high-dose fish oil supplements are indicated 
for use in hypertriglyceridemia (AHA). Fish oils contain 
the omega-3 fatty acids eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA), which have potent anti-in-
flammatory effects stemming from their ability to inhibit 
cyclooxygenase, an essential enzyme required for the 
formation of prostaglandins and thromboxane.24 Reducing 
inflammation, coupled with the inhibition of pro-athero-
sclerotic mediators25, likely account for EPA and DHA’s po-
tent plaque stabilization characteristics. These fatty acids 
are also believed to reduce triglyceride levels through nu-
merous mechanisms including the modulation of nuclear 
transcription factors associated with lipogenesis.26 Studies 
are underway to further elaborate on the benefits of ome-
ga-3 fatty acids on other conditions including 
rheumatoid arthritis, hypertension and depression.
Interaction
A study by Shahar et al. regarding atherosclerosis risk and 
omega-3 fatty acids showed that fish oils may decrease 
fibrinogen, factor VIII, and Von Willebrand factor (vWF), 
as well as increase protein C.27 Fish oil’s possible interac-
tion with platelets and clotting factors raises concern over 
their potential to increase bleeding risk in patients. This 
concern is further compounded when fish oils are taken 
by patients who are already on antiplatelets or anticoagu-
lants, as this may lead to severe bleeding events. In 
addition to the additive anti-atherothrombic actions of 
fish oils with warfarin, EPA and DHA may cause increased 
bleeding due to interactions that result in decreased 
platelet aggregation28, decreased platelet derived growth 
factor-like proteins29, and decreased platelet activating 
factor.30 In fact, increases in baseline INR have been re-
ported in patients who have significantly increased their 
doses of fish oil to ~2g/day while taking warfarin.31 
One randomized-controlled trial that included 610 
subjects showed no difference in bleeding in patients 
using high-dose (4g) fish oil therapy versus control.32 The 
study also found no increase in bleeding time between 
the two groups, though it did acknowledge that 
investigation of larger doses may be warranted. The 
researchers also measured plasma beta-thromboglobu-
lin levels among the participants, which increases with 
platelet activation, and found no difference between the 
study and control groups. Another randomized-controlled 
trial, which included patients on chronic warfarin therapy, 
showed no difference in lead-in INR and treatment INR 
among study groups.33 As the participants were stratified 
into groups that received placebo, 3g fish oil, or 6g fish 
oil, no differences in INR were noted among the different 
groups. In this study, Bender et al. conclude that fish oil 
supplementation of up to 3-6g/day does not significantly 
affect the safety of patients taking warfarin.
Recommendation
In spite of these studies, there is not enough definitive 
evidence that validates the relationship between the 
use of fish oils and increased bleeding time. So how are 
healthcare professionals to respond when faced with pa-
tients taking fish oil supplements along with their 
antithrombic therapy? One proposed approach is to 
follow the guidelines that are applicable to other antico-
agulants.34 This entails the reduction of fish oil consump-
tion or discontinuation of fish oils supplementations when 
the patient is suffering from acute bleeding illnesses like 
hemorrhagic stroke. Also, the discontinuation of fish oils 
before surgical procedures (to decrease the risk of bleed-
ing) and restarting these therapies following major 
operations (for its antithrombotic effects) should be 
considered. For all cases, it is the duty of healthcare 
professionals to weigh the risks and benefits of fish oils in 
patients who are at increased risk for bleeding 
complications. 
Red Yeast Rice
Red yeast rice (RYR) has been consumed for thousands 
of years since its use as a food spice in Asia. It is prepared 
by fermenting rice with the mold Monascus purpureus 
(M. purpureus) under sterile and controlled conditions. 
The ultimate product contains starch, sugar, sterols, iso-
flavones, pigments, fatty acids and, most notably, yeast 
polyketides.35 These polyketides consist of monacolins 
that include monacolin K, a compound that is identical 
in structure to lovastatin, an HMG-CoA reductase inhib-
itor; hence there was a controversy over its status as an 
OTC product, since it contains an FDA regulated drug. 
In May 1998, the FDA took the stance that RYR supple-
ments containing lovastatin are unapproved drugs.36 This 
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was upheld by several courts and the FDA began enforcing 
this edict. Currently, labels of RYR products do not contain 
information on levels of lovastatin and many do not contain 
lovastatin at all. Those that do are considered illegal, as 
emphasized by a consumer warning issued in 2007.37 
The clinical efficacy of RYR products containing lovastatin 
has been demonstrated by several groups.38 In addition to 
reducing total cholesterol and LDL levels, it decreases the 
frequency of major coronary events. Studies have found 
that RYR products containing 2-5 mg of lovastatin have 
similar efficacy to 20 mg of lovastatin.39 This suggests that 
there are additive and/or synergistic effects of the various 
components of RYR such as isoflavonoids, monounsaturat-
ed fats, and sterols.38 There is no specified role for RYR in 
updated hyperlipidemia guidelines,20 and it is briefly 
mentioned as alternative or adjunct therapy in ESC/EAS 
guidelines.40 Sales of RYR increased 80% between 2005 and 
2008 to $20 million,36 making it vitally important for 
pharmacists to be aware of its uses and limitations.
Interaction
Since RYR is defined as a dietary supplement, it is regulated 
by Current Good Manufacturing Practices (cCGMP) 
published by the FDA.37 These regulations not only require 
that companies produce products that are consistent, but 
also that they are not adulterated and correctly labeled. A 
few studies validating the contents of RYR products have 
been performed.
        The first study conducted in 2001, analyzed nine pro-
prietary Chinese RYR dietary supplements.41 The amount of 
total monacolin K ranged widely from 0.15 to 3.37 mg/cap-
sule. Moreover, they found citrinin, a compound that causes 
kidney failure in animals and genotoxic in cultured human 
lymphocytes at high doses, in seven of the nine samples. 
In 2010, Gordon et al. examined these and other indices of 
product purity.36 Similar to previous findings, there was a 
wide variability in ingredients among the different products: 
total monocolins ranged from 0.31 to 11.15 mg/capsule, 
monocolin K was 0.10 to 10.09 mg/capsule, and monocolin 
KA was 0.00 to 2.30 mg/capsule. Put in terms of total daily 
dose following serving recommendations, this would be a 
range of 2.71 to 24.71 total monacolins. Four products had 
elevated levels of citrinin. The authors of the most recent 
study directly contacted the FDA regarding RYR oversight.37 
The FDA admitted to having no information on the number 
of RYR manufacturers or distributors, and also reported 
that they are not able to ensure whether these products 
are consistent with cGMP regulations. These researchers 
did not quantify the active ingredients in the products, but 
rather looked at their labeling. They found that only 43 of 70 
products had statin-related warnings, and none of the 101 
products had been confirmed to pass a verification test (i.e. 
USP, Consumer Labs, NSF, or NPA). Moreover, several were 
combination products with other lipid-lowering agents (e.g. 
coenzyme-Q10, niacin and fish oil), vitamins (e.g. folic 
acid, vitamin B6, and vitamin B12), and dietary 
supplements.
       In addition to the wide variability of ingredients in 
RYR products, there are many safety monitoring 
parameters that need to be considered. Relative to 
lovastatin, RYR extracts were found to inhibit all six 
CYP450 enzymes tested (CYP2B6, 2C9, 2C19, 3A4, 1A2 
and 2D6) and P-glycoprotein (P-gp) to a greater 
extent,39 so drug-drug interactions should be assessed. 
Although most trials have found RYR to be well-tolerat-
ed, cases of myopathy, rhabdomyolysis, hepatotoxicity, 
and anaphylaxis have also been reported.38, 40 
Furthermore, it is considered a pregnancy category X 
with documented fetal abnormalities and should be 
taken with caution in patients with renal/hepatic 
impairment. Lastly, since it is a yeast product, it should 
not be taken if the patient is allergic to yeast products.
Recommendations
As with all supplements, great care should be taken 
in helping a patient select a RYR, especially given that 
there are numerous discrepancies and variability in 
content. Despite the FDA’s prohibition on lovasta-
tin-containing RYR products, they have done little to 
actually regulate and enforce this. Thus, pharmacists 
must be able to counsel patients inquiring about RYR, 
especially about its safety concerns. Quantity and 
quality may vary not only from manufacturer to man-
ufacturer, but from batch to batch or even bottle to 
bottle as well. Patients should be cautioned against its 
use despite its proven efficacy, due to safety concerns 
of consuming unknown amounts of a FDA approved 
drug with known drug-drug interactions and side 
effects. If patients have untreated dyslipidemia and are 
self-medicating with RYR, they may be directed to other 
OTC products or supplements that do not contain an 
active drug ingredient. They should also be advised on 
non-pharmacological treatment options like lifestyle 
changes. The best thing an individual could do is speak 
with their physician about a cost-effective FDA regulat-
ed pharmacological therapy option, with monitoring for 
safety and counseling on its use.
St. John’s Wort and Statins
St. John’s wort (Hypericum perforatum) is an OTC 
herbal supplement that is widely used in the U.S., and 
stands as the second best-selling herbal medicine 
product in the nation.43 Although a meta-analysis of 29 
trials concluded that St. John’s wort extract was 
superior in treating depression versus placebo44, 
multiple randomized controlled trials have failed to 
show its efficacy as a treatment for depression.45,46 The 
current American Psychiatric Association’s guidelines 
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for treating major depressive disorder states that St. John’s 
wort is not recommended for use in treating depression, due 
to the lack of evidence and regulation.47 However, St. John’s 
wort is still commonly being used by the U.S. population as an 
OTC self-treatment agent for depression.  
        St. John’s wort contains an array of compounds that 
may contribute to its potential pharmacological activities, 
including two compounds: hyperforin and hypericin.48 In 
particular, hyperforin has been identified as an inhibitor of 
several neurotransmitters including serotonin, norepineph-
rine, and dopamine.49 However, St. John’s wort also presents 
with it an increased risk of drug-drug interactions due to the 
enzyme-inducing properties associated with its natural com-
pounds.50 Such activity may decrease the serum drug levels of 
medications, thereby jeopardizing the therapeutic efficacy of 
many prescription medications. One possible interaction with 
St. John’s wort that has been identified in trials is associated 
with HMG-CoA reductase inhibitors, also known as statins. As 
statins are one of the most dispensed prescription medications 
in the U.S.51, the prevalence of a drug interaction with popular 
natural products like St. John’s wort is highly likely. In order to 
ensure the efficacy of treatment in patients with hyperlipid-
emia, an assessment for possible drug interactions is 
warranted in individuals who are taking statin medications.  
Interaction
St. John’s wort is an inducer of both CYP3A4 and P-gp, which 
are involved in the metabolism of many drugs in the human 
body.52,53 This induction may be explained by St. Johns wort’s 
role as a ligand for the nuclear pregnane X receptor (PXR). 
Activation of the PXR increases the expression of both P-gp 
and CYP3A4, so increased levels of St. John’s wort induces the 
expression of P-gp and CYP3A4 in the human body.54 Anoth-
er source of interaction is the natural compound hyperforin, 
which has been identified as an inducer of CYP3A455, an 
enzyme that is responsible for metabolizing about 50% of all 
prescription medications on the market.50 
        Atorvastatin, simvastatin, and lovastatin have been 
identified as CYP3A4 substrates56, while atorvastatin and 
simvastatin are also substrates of P-gp.57 Therefore, the 
concomitant use of St. John’s wort with these statin medica-
tions leads to an increase in statin metabolism, resulting in 
diminished efficacy. Several studies have demonstrated the 
effect of this drug interaction. (Table 1) 
        One randomized, double-blind study showed that taking 
St. John’s wort for 2 weeks prior to taking simvastatin resulted 
in a statistically significant decrease in the serum concentra-
tion and the AUC of active simvastatin metabolite.58 Another 
randomized-controlled trial tested the significance of this 
interaction in 16 patients with hypercholesterolemia who were 
being treated with a stable dose of atorvastatin. When 
atorvastatin was taken daily with St. John’s wort, statistically 
significant increases were observed in both the serum LDL 
and total cholesterol levels, representing a decreased efficacy 
of clinical importance.53 Another study featured 24 
patients with hypercholesterolemia who were being 
treated with a stable dose of simvastatin. Similar to a 
previous study, concomitant use resulted in 
significantly increased levels of serum LDL and total 
cholesterol.59 
Table 1. St. John's wort and its effect on antihyperlipidemic therapy 
 Sugimoto et al.58 Andren et al.53 Eggertsen et al.59 
Demographics 16 healthy 
volunteers 
16 patients with 
hypercholesterolemia 
24 patients with 
hypercholesterolemia 
Statin Simvastatin Atorvastatin Simvastatin 
Dose/frequency 10mg x1 on day 14 10mg-40mg* daily 10-40mg* daily 
SwJ dose/frequency 300mg TID 300mg BID 300mg BID 
Duration 14 days 4 weeks 4 weeks 
Effect Decreased serum 
simvastatin active 
metabolite 
Decreased AUC 
(metabolite) 
Increased LDL 
(p=0.004) 
Increased total 
cholesterol (p=0.02) 
Increased LDL 
(p<0.0001) 
Increased total 
cholesterol 
(p<0.0001) 
Increased 
triglycerides in 
females (p=0.036) 
*Indicates the stable dose of medication each patient was originally being treated with. 
  
 
        The increased levels of LDL and total cholesterol 
demonstrated in these studies have a direct influence 
on the clinical outcomes of patients who are on statin 
medications. Excess LDL circulating in the blood can 
get oxidized and turn into foam cells, eventually turn-
ing into atherosclerotic plaques.60 Increased plasma 
concentration of oxidized LDL has also been associated 
with increased risk of chronic heart disease.61 The 
inadequate control of total cholesterol and LDL levels 
in hyperlipidemic patients using St. John’s wort and 
statins may lead to potentially life-threatening clinical 
outcomes associated with the increased risk of 
cardiovascular disease. 
Recommendations
St. John’s wort is a popular OTC supplement which 
is widely used as an alternative treatment option 
for depression. However, it poses risks of numerous 
drug-drug interactions as an inducer of many drug-me-
tabolizing pathways in the human body. A pharmacist 
should educate patients about the lack of consistent 
evidence for the efficacy of St. John’s wort, and APA 
guideline recommendations against its use as a 
general treatment for treating depression. 
         Every patient who is on simvastatin, atorvasta-
tin, or lovastatin must be screened for the use of St. 
John’s wort. When a concomitant use is identified, the 
patient must be educated about the potential drug 
interactions associated with this supplement, including 
the potential decrease in the control of hyperlipid-
emia. Because it is difficult to detect the diminished 
efficacy of statin medication in a short-term period, it 
is important for patients to be aware of this interac-
tion. The patient should also be encouraged to engage 
in an active conversation with the physician about the 
efficacy of the statin treatment, with a possible in-
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crease in the dose of the statin medication or the initiation 
of a new antidepressant. 
Grapefruit Juice and Statins
While the concomitant use of two different drugs can 
result in adverse events due to drug-drug interactions, 
consuming certain food products while taking a medica-
tion can also influence the pharmacokinetics of drugs and 
ultimately affect the clinical efficacy of the medication. 
Grapefruit juice is a product that has numerous food-drug 
interactions, including calcium channel blockers, CNS 
modulators, and statins. Although no single constituent 
has been identified as the cause of these interactions, 
grapefruit juice contains many naturally-occurring com-
pounds such as flavonoids and furanocoumarins which 
have been found to have inhibitory effects on CYP3A4 
and P-gp.56 The concurrent intake of statins with sub-
stances that inhibit metabolic enzymes has been shown 
to increase statin serum concentration levels, which may 
increase the risk of undesirable side effects such as rhabo-
myolysis or renal failure. 
       According to the new 2013 ACC/AHA guidelines, 
statins are recommended as the primary pharmaceutical 
therapy for treatment of blood cholesterol to reduce the 
risk of ASCVD.20 The Centers for Disease Control and 
Prevention’s report on prescription drug use revealed 
that the use of antihyperlipidemic medications in the U.S. 
doubled between 1999 and 2010.62 The trend in increased 
use of statins is most likely to continue since the new ACC/
AHA guidelines greatly expanded the criteria for statin 
use. As grapefruit juice and grapefruit are common foods 
that are widely consumed by the public, assessment for 
possible food-drug interactions is warranted for patients 
who are taking statin medications.
Interaction
Several statin medications such as atorvastatin, 
lovastatin, and simvastatin are metabolized through the 
CYP3A4 enzyme.56 This predisposes patients that use 
these medications to possible drug interactions when used 
concomitantly with agents that inhibit or induce CYP3A4. 
Pravastatin, fluvastatin, pitavastatin and rosuvastatin have 
been shown to be metabolized by CYP3A4 at a lesser 
degree63, decreasing the possible risk for interactions 
with substances that affect CYP3A4. As demonstrated by 
several randomized controlled studies, grapefruit juice is 
one such substance that inhibits CYP3A4 in the small intes-
tine64 and increases the plasma concentration of statins 
with concomitant use. (Table 2) 
        The daily consumption of double-strength grapefruit 
juice prior to initiating statin medications has been shown 
to produce a statistically significant increase in the area 
under the plasma concentration-time curve (AUC) and the 
peak serum concentration  (Cmax) of simvastatin, 
atorvastatin, and their active metabolites.65,66,67 Similar 
results occurred in studies that used regular strength 
grapefruit juice.68,69 However, trials that demonstrated 
increased serum statin levels were mostly conducted 
with healthy, male volunteers and not patients who were 
already taking statin medications for hyperlipidemia. (Table 
2) Therefore, the data is not representative of the actual 
population of patients who are at risk of potential adverse 
events associated with prolonged statin use. 
Table 2. Effect of grapefruit juice consumption on serum statin concentration 
 
 kantola 
et al.65 
Lilja et 
al.66 
Lilja et al.67 Lilja et 
al.68  
 
Fukazaw
a et al.69 
Ando et 
al.70  
Demographi
cs 
10 
healthy 
voluntee
rs 
10 
healthy 
volunteers 
12 healthy 
volunteers 
10 
healthy 
volunteers 
20 healthy 
volunteers 
8 healthy 
volunteers 
Statin Lovastati
n 
Simvastat
in  
Atorvastatin Simvastat
in 
Atorvastat
in 
Atorvastat
in 
Dose 80mg x1 
on day 3 
60mg x1 
on day 3 
40mg x1 on 
day 3 
40mgX1 
on day 3 
10mg x1 
on day 3 
20mg 
daily  
gFJ 
dose/freq 
DS 
200mL 
TID 
DS 
200mL 
TID 
DS 200mL TID RS 200 
mL daily 
RS 250mL 
TID 
RS 250mL 
TID 
Duration 3 days 3 days 3days 3 days  3 days 4 days 
Effect  
Increase
d Cmax, 
AUC 
Increased 
 Cmax, 
AUC 
 
Increased   
 AUC, 
Cmax(metaboli
te) 
 
Increased  
Cmax, 
AUC 
Increased  
AUC,  
Cmax 
(metabolit
e) 
 
Increased 
AUC 
 
While increased blood level of statins may possibly result 
in an increased risk of myopathy71, it is unclear whether a 
linear relationship exists between the changes in plasma 
concentration of statins and the risk of adverse events.72 
Multiple variables influence the risk of such adverse 
events, such as the rapid change in drug concentration, 
use of other lipid-lowering therapy, and genetic factors.73 
In fact, while one study utilizing daily doses of atorvas-
tatin and grapefruit juice showed an increase in AUC of 
the drug, a wide variation in the AUC of atorvastatin was 
also present among the individuals in the control group 
that had consumed water instead of grapefruit juice.70 
The polymorphisms in CYP enzymes and transporters may 
produce inherent differences in each individual’s ability 
to metabolize statins74 and may account for the varying 
response and efficacy of statins in different patients. 
Nevertheless, an analysis of FDA Adverse Event reports 
show that about 55% of all statin-associated rhabdomy-
olysis are suspected to be the result of drug-drug interac-
tions75 and multiple cases of rhabdomyolysis have been 
reported in patients who regularly consumed grapefruits 
or grapefruit juice while they were on statin medica-
tions.76,77,78 Although it is not possible to know the exact 
clinical consequence in each patient taking statins and 
grapefruit juice, there is a definite risk of potentially 
harmful interactions with the concomitant use.  
Recommendations
In order to ensure the safety of patients taking statin 
medications, each patient should be educated about 
the possible drug interactions of statins and the risk of 
potentially serious complications that could arise as a 
result of the interactions, such as rhabdomyolysis. Before 
dispensing the medication, a pharmacist should screen the 
patient’s profile for possible drug-drug interactions and talk to 
the patient about the possible risk of drug-food interactions. 
For patients taking simvastatin, atorvastatin, or lovastatin, 
the pharmacist should ask the patient about grapefruit or 
grapefruit juice consumption, and educate the patient about 
the possible adverse events associated with this interaction. 
In order to eliminate the risk of a possible adverse event, it 
may be advisable to discourage the concomitant use of these 
medications with grapefruit juice. Consuming large amounts 
of grapefruit juice (more than a quart per day) while on these 
medications should be discouraged in these patients.79 Statin 
medications that do not confer the risk of this interaction and 
thus could be considered as alternative treatment options 
include pravastatin, fluvastatin, and rosuvastatin.80
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1. Which of the following is not typically a 
sign or symptom of chronic anemia? 
    a. Weakness
    b. Tachycardia
    c. Headache
    d. Cold sensitivity
2. Which medication does not decrease the 
absorption of oral iron products? 
    a. Levothyroxine
    b. Antacids
    c. Cholestyramine
    d. Proton pump inhibitors 
3. Which of the following is true regarding 
vitamin B12 deficiency? 
    a. Oral therapy is not preferred due to 
only 10% absorption 
    b. Pernicious anemia, a form of B12 
deficiency, is characterized by high values of 
intrinsic factor
    c. Replacement therapy is rarely long 
term, with the issue usually resolving in 3-6 
weeks 
    d. Though a serious outcome, neurolog-
ical symptoms often resolve within a few 
days of treatment if treated early on 
4. Which oral iron product contains the 
highest percent of elemental iron? 
    a. Ferrous gluconate
    b. Ferrous sulfate
    c. Ferrous fumarate
    d. Polysaccharide-iron complex 
5. Which food is/are a good source of vita-
min B12? 
    a. Meat
    b. Fish
    c. Eggs
    d. Dairy 
    e. All of the above 
6. What is the most common side effect 
of oral iron therapy? 
    a. Headache 
    b. Nausea
    c. Rash 
    d. Joint pain 
7. If a patient experiences the side 
effect describe above (#6) what is the 
best way to try to prevent further com-
plications? 
    a. Discontinue oral therapy 
    b. Instruct the patient to take the 
    tablets in one daily dose 
    c. Recommend the patient takes 
     antacids 
    d. Recommend the patient try taking 
the tablets with orange juice 
8. True or False: Intravenous iron su-
crose is FDA approved for the treatment 
of iron-deficiency anemia 
 
 9. Which of the following statements 
about folate deficiency is false? 
    a. Laboratory evaluations will include 
a low MCV    
    b. Alcoholism is a risk factor 
    c. Green leafy vegetables are a good 
source of folate 
    d. Irritability and memory 
impairment can be symptoms 
Use the following patient case for 
questions 10-12: 
TD is a 69 year-old female who 
presents with dyspnea on exertion, 
intermittent chest pain, cough and 
fatigue. Her lab values at this time are 
as follows: 
 
 
 
 
 
CBC Iron Studies Other 
Hgb 8g/dL Serum iron 9mcg/L MCV 72 fL/cell 
Hct 26.0% Ferritin 1 ng/mL Reticulocyte count 3.3% 
RBC 3.94 x 106 
uL 
TIBC 490 mcg/dL Vitamin B12 440 pg/mL 
 TSAT 2% Folic acid 6.4 mcg/L 
10. What type of anemia do these lab 
values indicate? 
    a. Iron deficiency anemia
    b. Vitamin B12 deficiency anemia
    c. Folate deficiency anemia
    d. Pernicious anemia 
11. Which of the following would be an 
appropriate treatment for TD’s condi-
tion? 
   a. Vitamin B12 1000mcg PO daily 
   b. Ferrous gluconate 300mg PO daily
   c. Folic acid 0.4mg IM daily 
   d. Ferrous sulfate 300mg PO TID 
12. Which of the following statements is 
false regarding TD’s therapy? 
   a. Taking her medication with orange 
juice will increase its absorption 
   b. It is expected that TD’s Hgb should 
increase by 5g/ dL per week 
   c. TD may experience dark stools 
   d. Eating meat and beans could help 
aid in her treatment 
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I.
      A Review of Common Drug-drug and Food-drug Interactions Associated with Cardiovascular Medications
ACPE UAN# 0100-0000-14-070-H01-P / 0100-0000-14-070-H01-T
II.
1.  What is the concern regarding 
concomitant use of PPIs and clopido-
grel? 
   a. PPIs and clopidogrel present a 
duplication   of therapy
   b. PPIs may inhibit the activation of 
clopidogrel causing increased CV risks
   c. PPIs may cause increased hepatic 
elimination of clopidogrel causing 
increased CV risks
   d. Toxic accumulation of PPIs may 
occur because clopidogrel are also 
metabolized by CYP2C19. 
2.  Which of the following medications 
used for the regulation of gastric acid 
production presents the most concern 
when used with antiplatelet agents 
like clopidogrel? 
    a. Omeprazole
    b. Pantoprazole
    c. Ranitidine
    d. Famotidine
3.  An elderly patient with a history 
of GI bleed presents to the pharmacy 
to refill his Plavix. He has a history of 
CVD and just underwent surgery for placement of 
a coronary stent a week ago. You notice that he is 
taking Plavix with aspirin, as well as pantoprazole 
for bleeding prophylaxis. Your response should be: 
   a. Consult the prescribing physician, as you 
should with every case taking PPIs and dual-anti-
platelet therapy
   b. Advise the patient to space out the dosing of 
his PPI, at least 4 hours apart from his antiplatelet 
medications 
   c. Call the hospital. The patient is at high risk of a 
sudden CV event
   d. Refill the Plavix because PPIs are indicated in 
this patient based on his risk for GI bleed. 
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5.   Fish oils show benefit in reducing 
atherosclerosis because of their ability to 
     a. Inhibit cyclooxygenase
     b. Increase prostaglandins and 
      thromboxane
     c. Decrease platelet aggregation
     d. Modulate nuclear transcription factors
6.  Patient YL has been recently discharged 
from the hospital following valve 
reconstruction surgery. She would like to 
continue taking her fish oil supplements for 
her high triglyceride levels. How would you 
respond to her? 
   a. She can no longer take her fish oil 
supplements due to its ability to increase 
bleeding risk
   b. She can no longer take her fish oil 
supplements because they will no longer be 
effective
   c. She no longer needs fish oil 
supplementation because she had 
major heart surgery
   d. She can restart her fish oil 
supplements once she is cleared by her 
physician
7. What is the possible explanation for the 
drug interaction between statin drugs and 
grapefruit juice? 
   a. Grapefruit juice is an inducer of the 
enzyme that metabolizes statins
   b. Grapefruit juice worsens hyperlipidemia 
in patients taking statin medications
   c. Grapefruit juice is an inhibitor of the 
enzyme that metabolizes certain statins. 
   d. Grapefruit juice is an inhibitor of the 
enzyme that matabolizes all statins. 
8. Mrs. Jones is a 55 year-old female who 
was prescribed a new drug regimen for her 
could help with her cholesterol. She is 
currently not taking anything for hyper-
lipidemia due to finances. What should 
be a justified recommendation? 
    a. Yes, take RYR because it contains a 
FDA regulated drug used for hyperlip-
idemia
    b. Yes, tkae RYR but only purchase a 
product with consistent levels of mon-
acolin K
    c. No, do not take RYR because it has 
not been shown to be effective 
    d. No, taking RYR is not recommend-
ed due to quality concerns as well as 
safety concerns 
CONTINUING EDUCATION
4. Which of the following contributes to the 
concern over fish oil supplementation in 
conjunction with warfarin therapy?
   a. The cost of fish oil supplementation and 
warfarin therapy would be excessive
   b. Fish oils would inhibit the effects of 
warfarin therapy
   c. Omega-3 fatty acids may decrease 
fibrinogen, factor VIII, and Von Willebrand 
factor (vWF), which may increase risk of 
bleeding 
   d. Omega-3 fatty acids may decrease 
protein C, which may increase risk of 
bleeding 
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hyperlipidemia. (Simvastatin 20mg PO 
daily). However, after watching Dr. Oz 
talk about drug side effects on TV last 
night, she is hesitant to take her medi-
cation and asks for your opinion. What 
would you tell her? 
   a. Statins are known to be safe 
medications with no significant drug 
interations
   b. Statins are associated with side ef-
fects involving muscle pain and disorder
   c. Drinking large quantities of grape-
fruit juice regularly while on this 
medication could result in a rare but 
serious muscle disorder 
    d. B and C
9. According to new hyperlipidemia 
guidelines, niacin would be recom-
mended to treat hyperlipidemia for 
which of the following patient popula-
tions?  
   a. First-line for a patient newly 
diagnosed with dyslipidemia
   b. With elevated non-HDL-C and at 
target LDL-C to reduce ASCVD outcomes
   c. With high-risk and intolerant to 
statin therapy
   d. Not recommended given the lack of 
support in clinical trials
10.  Which statement is correct about 
niacin formulations?  
   a. IR products are associated with 
hepatotoxicity
   b. Niaspan is the only FDA approved 
ER product and has relatively moderate 
risks of hepatotoxicity and flushing 
   c. SR products are associated with 
flusing 
   d. All formulations (IR, SR, and ER) are 
available OTC. 
11. RYR is a dietary supplement that
    a. Is actively regulated by the FDA be-
cause it contains a FDA regulated drug
    b. Is considered to be illegally market-
ed if it contains monacolin K
    c. Has been found to have consistent 
levels of active ingredients 
    d. Is recommended as an alternative 
or adjunct therapy in updated 
hyperlipidemia guidelines.
12. A woman approaches you stating 
she heard RYR is a natural product that 
13. Mrs. Young is a 50-year old female 
who is taking Atorvastatin 20mg PO 
daily for hyperlipidemia. After talking 
to her, you discover that she is also 
taking a daily dose of St. John’s word 
600mg for depression. What is (are) the 
appropriate counseling point(s) for Mrs. 
Young? 
   a. St. John’s wort is a safe and ef-
fective, FDA-approved treatment for 
depressive disorders
   b. There is a risk of potentially harmful 
drug interaction if atorvastatin is used 
with St. John’s wort
   c. St. John’s wort may decrease the 
efficacy of atorvastatin
   d. B and C. 
14. What is the possible explanation for 
the interaction between St. John’s wort 
and Statin drugs? 
   a. St. John’s wort is an inducer of 
CYP3A4 and P-gp
   b. St. John’s wort is a competitive 
inhibitor of statin drugs
   c. St. John’s wort is an inhibitor of 
CYP3A4 and P-gp
   d. Statins enhance the therapeutic 
effect of St. John’s wort
15. What is a possible adverse drug 
event associated with the consumption 
of large quantities of grapefruit juice on 
statin therapy? 
   a. Rhabdomyolysis
   b. Stevens-Johnson Syndrome
   c. Reye Syndrome 
   d. Acute pancreatitis 
